Linked Life Data

15700334

Source:http://linkedlifedata.com/resource/pubmed/id/15700334

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-2-8
pubmed:abstractText
Hepatocellular carcinoma (HCC) is the leading cause of death in liver cirrhosis. Ultrasound (US) is widely accepted as the screening imaging modality of choice for HCC in patients with a history of chronic liver disease. However, the US characteristics of HCCs are non-specific and thus, other imaging techniques or biopsy are usually necessary to characterize focal liver lesions (FLL) and confirm malignancy. Blood flow to HCC is mainly arterial, making dynamic CT and MRI the most commonly used techniques to detect the characteristic arterial hypervascularization. Recently, the development of second-generation US contrast agents and microbubble-specific software has changed the role of US in real-time evaluation of the macro and microvascularization of FLLs. With this technology, the accuracy of US in the diagnosis of HCC and its differentiation from other FLLs such as regenerating nodules has improved dramatically. In addition, contrast-enhanced ultrasound may also be a useful tool in the staging of HCC and in the evaluation of percutaneous treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0938-7994
pubmed:author
pubmed:issnType
Print
pubmed:volume
14 Suppl 8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
P63-71
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
The use of contrast-enhanced ultrasound in the management of the cirrhotic patient and for detection of HCC.
pubmed:affiliation
Imaging Diagnosis Center, Hospital Clinic, 08036 Barcelona, Spain. cnicolau@clinic.ub.es
pubmed:publicationType
Journal Article